Quest Diagnostics (NYSE:DGX) is scheduled to issue its quarterly earnings data before the market opens on Tuesday, July 23rd. Analysts expect the company to announce earnings of $1.70 per share for the quarter. Quest Diagnostics has set its FY 2019 guidance at $6.40 EPS.Parties that wish to listen to the company’s conference call can do so using this link.
Quest Diagnostics (NYSE:DGX) last released its quarterly earnings data on Tuesday, April 23rd. The medical research company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.36 by $0.04. Quest Diagnostics had a return on equity of 14.99% and a net margin of 9.59%. The company had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.87 billion. During the same period last year, the business posted $152.00 EPS. Quest Diagnostics’s quarterly revenue was up .4% on a year-over-year basis. On average, analysts expect Quest Diagnostics to post $6 EPS for the current fiscal year and $7 EPS for the next fiscal year.
Shares of NYSE:DGX opened at $99.28 on Monday. Quest Diagnostics has a 12-month low of $78.95 and a 12-month high of $115.64. The firm has a fifty day moving average of $100.76. The stock has a market cap of $13.34 billion, a P/E ratio of 15.73, a PEG ratio of 2.02 and a beta of 0.86. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.78 and a quick ratio of 0.74.
In other Quest Diagnostics news, insider Mark Guinan sold 73,005 shares of Quest Diagnostics stock in a transaction dated Thursday, June 13th. The stock was sold at an average price of $100.00, for a total transaction of $7,300,500.00. Following the completion of the sale, the insider now owns 139,022 shares of the company’s stock, valued at approximately $13,902,200. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Chairman Stephen H. Rusckowski sold 244,565 shares of Quest Diagnostics stock in a transaction dated Thursday, June 13th. The stock was sold at an average price of $100.00, for a total value of $24,456,500.00. Following the sale, the chairman now directly owns 457,614 shares of the company’s stock, valued at approximately $45,761,400. The disclosure for this sale can be found here. Insiders sold a total of 365,144 shares of company stock valued at $36,276,530 in the last three months. Insiders own 1.86% of the company’s stock.
A number of brokerages have recently issued reports on DGX. Canaccord Genuity set a C$16.50 price target on Detour Gold and gave the company a “buy” rating in a report on Wednesday, April 24th. Jefferies Financial Group reiterated a “sell” rating on shares of Hi-Crush Partners in a report on Tuesday, April 2nd. ValuEngine downgraded Viewray from a “buy” rating to a “hold” rating in a report on Wednesday, April 24th. Goldman Sachs Group reiterated a “buy” rating and issued a $70.00 price target on shares of Total in a report on Monday, July 15th. Finally, Wolfe Research began coverage on Iqvia in a report on Tuesday, April 2nd. They issued a “market perform” rating on the stock. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have assigned a buy rating to the stock. Quest Diagnostics currently has a consensus rating of “Hold” and a consensus target price of $101.33.
Quest Diagnostics Company Profile
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.